Tag Archives: biologics

The Federal Circuit Declines to Revisit its Decision that the Biosimilars Patent Dance is Optional – Next Stop, Supreme Court?

By Tamara Fraizer on October 19, 2015 Posted in Healthcare, Patents

This past summer, a divided Federal Circuit panel found, in the case of Amgen v. Sandoz, that the so-called “patent dance” under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) is optional. This past Friday, the Federal Circuit declined to rehear that decision. Its decision provides biosimilar developers with continued choice while opening … Continue Reading